Make Better Decisions - Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

Get the Book: Make Better Decisions

Finding and Evaluating Generic and Branded Drug Market Entry Opportunities

PDF eBook: Just $10 Get Print Book on Amazon

Serving leading biopharmaceutical companies globally:

Boehringer Ingelheim
Baxter
Harvard Business School
Johnson and Johnson
McKesson
Merck

Last Updated: December 10, 2019

DrugPatentWatch Database Preview

Rilonacept - Biologic Drug Details

Join the DrugPatentWatch Referral Program
Get access to a free drug patent landscape report or a free one-month subscription

« Back to Dashboard

Summary for rilonacept
Tradenames:1
Patents:22
Applicants:1
BLAs:1
Suppliers: see list1
Recent Clinical Trials: See clinical trials for rilonacept
Recent Clinical Trials for rilonacept

Identify potential brand extensions & biosimilar entrants

SponsorPhase
Kiniksa Pharmaceuticals, Ltd.Phase 3
Kiniksa Pharmaceuticals, Ltd.Phase 2
Karoline KrausePhase 2

See all rilonacept clinical trials

Company Disclosures: US Patents for rilonacept

These patents were extracted from company disclosures
Applicant Tradename Biologic Ingredient Dosage Form BLA Number Approval Date Patent No. Assignee Estimated Patent Expiration Status Orphan Source
Regeneron Pharmaceuticals ARCALYST rilonacept VIAL; SINGLE-USE 125249 001 2008-02-27   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2013-10-20 RX Orphan company
Regeneron Pharmaceuticals ARCALYST rilonacept VIAL; SINGLE-USE 125249 001 2008-02-27   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2018-09-25 RX Orphan company
Regeneron Pharmaceuticals ARCALYST rilonacept VIAL; SINGLE-USE 125249 001 2008-02-27   Start Trial Regeneron Pharmaceuticals, Inc. (Tarrytown, NY) 2018-09-25 RX Orphan company
>Applicant >Tradename >Biologic Ingredient >Dosage Form >BLA >Number >Approval Date >Patent No. >Assignee >Estimated Patent Expiration >Status >Orphan >Source

Patent Text Search: US Patents for rilonacept

These patents were identified by searching patent claims

Supplementary Protection Certificates for rilonacept

Supplementary Protection Certificate SPC Country SPC Expiration SPC Description
2017000101 Germany   Start Trial PRODUCT NAME: SARILUMAB; REGISTRATION NO/DATE: EU/1/17/1196 20170623
90062-2 Sweden   Start Trial PRODUCT NAME: SARILUMAB; REG. NO/DATE: EU/1/17/1196 20170627
0100004 00030 Estonia   Start Trial PRODUCT NAME: ARCALYST-RILONACEPT; REG NO/DATE: C(2009)8377 23.10.2009
>Supplementary Protection Certificate >SPC Country >SPC Expiration >SPC Description

Make Better Decisions: Try a trial or see plans & pricing

Serving leading biopharmaceutical companies globally:

Moodys
Harvard Business School
Merck
Baxter
Mallinckrodt
Boehringer Ingelheim

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verifification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.